A 45-year-old with newly diagnosed nonsevere CDI asks about preventing recurrence after cure. Which evidence-based option reduces recurrence risk when...

Question

A 45-year-old with newly diagnosed nonsevere CDI asks about preventing recurrence after cure. Which evidence-based option reduces recurrence risk when treating the next episode?

Accepted Answer

Fidaxomicin instead of vancomycin

Answer

Metronidazole first-line

Answer

Cholestyramine with vancomycin

Answer

Prophylactic probiotics for all

Answer

Rifaximin monotherapy

us-abfm MCQ (SBA): C. difficile (Recurrence Prevention)

A 45-year-old with newly diagnosed nonsevere CDI asks about preventing recurrence after cure. Which evidence-based option reduces recurrence risk when treating the next episode?